INMB INmune Bio Corp: Earnings per share for the last twelve months
INmune Bio, Inc. (INMB) is driving a positive trajectory through its innovative approach to activating immunity against cancer and neuroinflammation, which is further validated by the trend in annual net income per share. This growth is underpinned by closed clinical protocols for macrophage therapy and the resilience of the healthcare sector against geopolitical risks in the US. The current value of the metric is -0.61, providing a real-time assessment of the business's actual yield relative to its market value.
Analytical breakdowns and data insights for company INmune Bio Inc (INMB)
- current quotes and average value forecast:
- company stock capitalization data:
- shareholders' equity book value data:
- debt and liquidity data:
Total Debt to Capital INmune Bio, Inc.|INMB - Long-Term Liabilities to Capital|Short-Term Debt to Capital INmune Bio Corp|INMB - Company Total Debt Obligations|Debt to Book Capitalization Ratio INmune Bio, Inc.|INMB - Company Long-Term Indebtedness|Company Short-Term Debt INmune Bio|Quick Liquidity Indicator inmunebio.com
- earnings and valuation multiples indicators:
INMB - Net Profit|Expected Profit INmune Bio, Inc.|INMB - Price to Earnings Multiple|Forward P/E Multiple INmune Bio|INMB - Price to Earnings Adjusted for Growth Rate|Enterprise Value to EBITDA Ratio INmune Bio, Inc.|INMB - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) INmune Bio|INMB - Earnings per share for the last twelve months|Quarterly EPS earnings growth inmunebio.com|INMB - Expected net earnings per share growth this year|Net earnings per share growth forecast for next year INmune Bio, Inc.
Fundamental company analysis:INMB - INmune Bio, Inc.
Experienced investors utilize yield filtering to select the most resilient assets. This indicator measures the total annual net income distributed per share, allowing for an assessment of real capital efficiency. For INmune Bio, Inc. (INMB), this calculation reflects the financial return from strategic alliances in the field of neuropharmacology. The synergy of Alzheimer's disease clinical trials directly impacts future capitalization. By analyzing the TTM earnings per share trend, one can forecast the pace of business scaling.
Direct competitors
ARGX - Earnings per share for the last twelve months|biontech.de (BNTX) - Net earnings per share for the last 12 months|Abivax Pharma (ABVX) - Earnings per share for the last twelve months|Net earnings per share for the last 12 months ADMA Biologics Inc|Net earnings per share for the last 12 months PTGX|Net earnings per share (EPS TTM) Immunovant Therapeutics|Earnings per share for the last twelve months Kiniksa Pharmaceuticals (KNSA)|grifols.com - Earnings per share for the last 12 months|Net earnings per share (EPS TTM) ADPT (Adaptive Biotechnologies Corporation)|Celldex Therapeutics Inc (CLDX) - Net earnings per one share for the last twelve months|Aurinia Pharma - Net earnings per share (EPS TTM)|Net earnings per share for the last four quarters BioCryst Corp BCRX|Vera Therapeutics, Inc. (VERA) - Earnings per share for the last twelve months|Earnings per share for the last 12 months DNTH|Earnings per share for the last twelve months Pharvaris|Net earnings per share for the last 12 months AbCellera Biologics Inc (ABCL)|Net earnings per share for the last 12 months TRML (Tourmaline Corp)|Net earnings per share (EPS TTM) Precigen Corp (PGEN)|Earnings per share for the last twelve months Pharming Group N.V. PHAR|NKTR: Earnings per share for the last 12 months|Upstream Bio - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Zenas Bio|IMNM (Immunome Corp) - Net earnings per share for the last 12 months|Gossamer Bio Corp. - Earnings per share for the trailing year|KALV (KalVista Pharmaceuticals) - Net earnings per share (EPS TTM)|Earnings per share for the last twelve months SEPN|Net earnings per share (EPS TTM) PVLA|Net earnings per share for the last four quarters Savara Inc|Earnings per share for the last twelve months Rigel Pharmaceuticals Inc RIGL|AnaptysBio Inc. (ANAB) - Net earnings per one share for the last twelve months|ATXS: Net earnings per share for the last 12 months|Earnings per share for the trailing year ENGN (engene.com)|RAPT: Net earnings per share (EPS TTM)|JBIO - Net earnings per share for the last four quarters|Earnings per share for the last twelve months Aclaris|Earnings per share for the last 12 months KYTX (Kyverna Therapeutics, Inc)|Net earnings per share (EPS TTM) TLSA|Net earnings per share for the last 12 months cabalettabio.com CABA|Ventyx Biosciences, Inc. - Net earnings per share for the last 12 months|Net earnings per share for the last four quarters Theratechnologies, Inc. (THTX)|Avalo Therapeutics Inc. - Net earnings per share (EPS TTM)|Net earnings per share for the last four quarters Eledon Pharmaceuticals, Inc ELDN|Agenus (AGEN) - Earnings per share for the last twelve months|Earnings per share for the last 12 months CLYM|Earnings per share for the last twelve months Zura Bio Limited|Net earnings per share for the last 12 months aTyr Pharma Inc (ATYR)|Net earnings per share (EPS TTM) ADAG|Earnings per share for the last twelve months IMA (ikenaoncology.com)|Earnings per share for the last twelve months Shattuck Labs STTK|EQ (Equillium Inc) - Earnings per one share for the last 12 months|Connect Pharma - Net earnings per share (EPS TTM)|Earnings per share for the trailing year IMUX (Immunic, Inc.)|ATRA: Net earnings per share (EPS TTM)|InflaRx (IFRX) - Net earnings per share (EPS TTM)|Earnings per share for the last twelve months X4 Pharmaceuticals|ACET: Earnings per share for the trailing year|Earnings per share for the last twelve months Celularity Inc. (CELU)|Net earnings per share for the last 12 months Barinthus Biotherapeutics PLC BRNS|Net earnings per share (EPS TTM) KZR (Kezar Life Sciences, Inc)|Net earnings per share (EPS TTM) SAB Biotherapeutics Inc SABS|AKTX: Net earnings per share for the last 12 months|Earnings per share for the trailing year ENLV (Enlivex Therapeutics)|QTTB: Net earnings per share (EPS TTM)|GOVX - Net earnings per share for the last four quarters|Earnings per share for the last twelve months Edesa|Net earnings per share for the last 12 months iBio Corporation (IBIO)|Earnings per share for the last twelve months Carisma Therapeutics (CARM)|Net earnings per share for the last 12 months xtlbio.com XTLB|Bolt Biotherapeutics, Inc. - Net earnings per share for the last 12 months|Net earnings per share (EPS TTM) HCW Biologics, Inc. HCWB|APVO - Earnings per share for the last twelve months|AIM (AIM ImmunoTech, Inc.) - Earnings per share for the last 12 months|ADTX: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months gribio.com (GRI)|XRTX (XORTX Therapeutics) - Net earnings per share (EPS TTM)|Vyome Holdings Inc. (HIND) - Net earnings per share for the last four quarters|Earnings per share for the last twelve months Revelation Bio (REVB)|Indaptus Corp - Earnings per share for the last 12 months|Earnings per share for the last twelve months Scinai Immunotherapeutics SCNI|CALI - Net earnings per share for the last 12 months|AFMD: Net earnings per share for the last 12 months|ALLK - Net earnings per share (EPS TTM)|hookipapharma.com (HOOK) - Earnings per share for the last twelve months|Earnings per share for the last 12 months IGMS|ITOS (iTeos Therapeutics) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months oceanbiomedical.com OCEA|Net earnings per share for the last 12 months TCBP (TC BioPharm)|THRD (Third Harmonic Bio Inc.) - Earnings per share for the trailing year
